Brand et al. (2016) discovered that LDHA-derived lactate reduced the ability of T cells and NK cells to conduct immune surveillance of cancer cells. Furthermore, Leone et al. (2019) reported the activation of different metabolic pathways through the blockage of glutamine in cancer cells to overcome immune invasion. Increasing evidence highlights the profound significance of metabolic heterogeneity in GC, which may explain the challenges faced by current therapeutics and in the prediction of clinical outcomes of GC patients (Zhang et al., 2020a; Zhu et al., 2021a). The gene discussed is LDHA; the disease is cancer.